Bevacizumab for Advanced Breast Cancer | Zendy

Shari Goldfarb | Zendy; Tiffany A. Traina | Zendy; Maura N. Dickler | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bevacizumab for Advanced Breast Cancer

Author(s) -

Shari Goldfarb,

Tiffany A. Traina,

Maura N. Dickler

Publication year - 2010

Publication title -

women s health

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.363

H-Index - 39

eISSN - 1745-5065

pISSN - 1745-5057

DOI - 10.2217/whe.09.71

Subject(s) - bevacizumab , medicine , oncology , docetaxel , breast cancer , angiogenesis , metastatic breast cancer , metastasis , paclitaxel , clinical trial , cancer , chemotherapy

Tumor angiogenesis is an important step in breast cancer development, progression, invasion and metastasis. Proangiogenic factors such as VEGF regulate angiogenesis and are targets for drug development. Bevacizumab, an anti-VEGF antibody, has demonstrated significant clinical benefit in several solid tumors, including breast cancer. Its use in combination with either paclitaxel or docetaxel has prolonged progression-free survival and increased response rates in the first-line treatment of patients with metastatic breast cancer. This review article discusses the clinical trials establishing the use of bevacizumab for the treatment of advanced breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research